Literature DB >> 9315472

IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes.

Y Lu1, M E Tschickardt, B J Schmidt, G Blanck.   

Abstract

We have previously reported that HLA class II induction by IFN-gamma is rescuable by reconstitution of functional retinoblastoma protein (RB) in two RB-defective tumour lines: the breast carcinoma line, MDA-468-S4 (S4) and the non-small cell lung carcinoma line, H2009. To determine the range of tumours and tumour types in which RB rescues HLA class II inducibility, we examined another RB-defective tumour line, the retinoblastoma line, WERI-Rb1. As in the case of S4 and H2009, HLA-DRA and -DRB were non-inducible by IFN-gamma in WERI-Rb1. However, neither inducibility of DRA nor DRB mRNA was resulted in an RB-positive stable transformant of WERI-Rb1, WLRB-8. While guanylate-binding protein (GBP) inducibility indicated that the basic IFN-gamma signal transduction pathway remained intact in WERI-Rb1, mRNA for class II transactivator (CIITA), a mediator of the IFN-gamma activation of the HLA class II genes and several other genes related to immune function, was not detectable in IFN-gamma-treated WERI-Rb1, indicating that the lack of CIITA expression was responsible, at least in part, for the inability of RB to rescue HLA class II-inducibility. The HLA class II-associated invariant chain (Ii), the expression of which is also up-regulated by CIITA, was non-inducible in WERI-Rb1, consistent with non-inducible CIITA. Also, IFN-gamma failed to activate the DRA, DRB and Ii promoters in WERI-Rb1. However, exogenous CIITA expression in WERI-Rb1 activated the DRA, DRB and Ii promoter-chloramphinocol acetyltransferase constructs, confirming that CIITA was not induced in WERI-Rb1 and indicating that other proteins required for activation of the class II and Ii promoters were functional in this cell line. Examination of additional cell lines for GBP and CIITA induction revealed that a specific lack of the CIITA IFN-gamma response is common in human tumour lines. The possible role of CIITA defects in tumorigenesis is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315472     DOI: 10.1038/icb.1997.50

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  10 in total

Review 1.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 2.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

Review 3.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

4.  MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development.

Authors:  John M Yavorski; George Blanck
Journal:  Mol Clin Oncol       Date:  2017-09-29

Review 5.  The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy.

Authors:  Jack Hutcheson; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes.

Authors:  Rajini Mudhasani; Joseph D Fontes
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

7.  Multiple kinases in the interferon-gamma response.

Authors:  D Watling; C R Carmo; I M Kerr; A P Costa-Pereira
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-15       Impact factor: 11.205

8.  Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Authors:  Peter J van den Elsen; Nienke van der Stoep
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

Review 9.  Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.

Authors:  Adithya Balasubramanian; Thomas John; Marie-Liesse Asselin-Labat
Journal:  Biochem Soc Trans       Date:  2022-04-29       Impact factor: 4.919

10.  Phorbol myristate acetate and Bryostatin 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell line.

Authors:  Yuri Kudinov; Charles L Wiseman; Alexander I Kharazi
Journal:  Cancer Cell Int       Date:  2003-03-25       Impact factor: 5.722

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.